HYLENEX RECOMBINANT: payments to doctors
Payments that named HYLENEX RECOMBINANT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $22K
- Providers
- 437
- Transactions
- 1,039
- Average per transaction
- $21
The per-transaction average — $21 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 437 providers the average total is $49, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Halozyme Inc | $16,893 | 78.2% |
| Supernus Pharmaceuticals, Inc. | $4,704 | 21.8% |